RxDoctor Payments Data

Ali Sheybani, MD

Internal Medicine · Sherman Oaks, CANPI 1427006824

Payments from drug & device makers

$3,801in general payments, 2019–2025

Across 189 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$977
  • Abbott$363
  • Exact Sciences$349
  • AstraZeneca$340
  • AbbVie$162
  • Optinose US, Inc.$158
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,76899%
  • Education$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,801 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$102,159
Medicare patients
226
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala13$60,003
OzempicSemaglutide57$56,160
JardianceEmpagliflozin36$42,780
Repatha SureclickEvolocumab52$38,330
LinzessLinaclotide44$36,684
JanuviaSitagliptin Phosphate31$25,743
ProliaDenosumab15$25,300
Diclofenac Sodium48$23,026
EliquisApixaban26$22,246
FarxigaDapagliflozin Propanediol14$18,241
Tresiba Flextouch U-200Insulin Degludec16$12,643
XareltoRivaroxaban14$12,152
MounjaroTirzepatide12$11,896
JubliaEfinaconazole13$9,569
Restasis MultidoseCyclosporine11$6,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$95$56,16057 claims
AbbVieLinzess, Restasis Multidose, Synthroid$162$44,53276 claims
Boehringer IngelheimJardiance$19$42,78036 claims
MerckJanuvia$11$25,74331 claims
AmgenProlia$977$25,30015 claims
PfizerEliquis$102$22,24626 claims
AstraZenecaFarxiga$340$18,24114 claims
Lilly USA, LLCMounjaro$129$11,89612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sherman Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →